msh (11-13) has been researched along with Brain Injuries in 1 studies
*Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engelhard, K; Jahn-Eimermacher, A; Kornes, F; Luh, C; Pieter, D; Schäfer, MK; Schaible, EV; Sebastiani, A; Steinsträßer, A; Thal, SC | 1 |
1 other study(ies) available for msh (11-13) and Brain Injuries
| Article | Year |
|---|---|
Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Brain; Brain Injuries; Calcium-Binding Proteins; Gene Expression; Inflammation Mediators; Male; Melanocyte-Stimulating Hormones; Mice; Mice, Inbred C57BL; Microfilament Proteins; Microglia; Peptide Fragments; Pro-Opiomelanocortin; Receptor, Melanocortin, Type 1; Receptor, Melanocortin, Type 4 | 2013 |